Motif Bio shares suspended from trading
29th Jul 2020 09:59
(Sharecast News) - Pharmaceutical company Motif Bio saw its shares suspended from trading on Wednesday in order to satisfy AIM rules.
Read moreMotif Bio raises ?0.65m as it hunts for reverse takeover opportunity
5th May 2020 09:17
(Sharecast News) - Motif Bio, which has been reclassified as an AIM rule 15 cash shell, has raised a total of ?0.65m before expenses via a placing, it announced on Tuesday, through the issue of 162,500,000 ordinary shares with an institutional investor at a price of 0.4p each.
Read moreMotif Bio struggling to find reverse takeover opportunity
18th Mar 2020 15:33
(Sharecast News) - Motif Bio updated the market on its corporate developments on Wednesday, having been reclassified as an AIM rule 15 cash shell.
Read moreMotif Bio reaches settlement with former clinical research organisation
11th Nov 2019 09:40
(Sharecast News) - Motif Bio announced on Monday that its subsidiary Motif BioSciences has reached an agreement with its former clinical research organisation to settle all obligations without further payment.
Read moreMotif Bio announces US Army-funded evaluation of 'iclaprim'
24th Oct 2019 16:05
(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
Read moreMotif Bio to work with Lamellar on cystic fibrosis treatment possibility
1st May 2019 10:46
(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.
Read moreMotif Bio crashes as FDA calls for more data
14th Feb 2019 11:47
(Sharecast News) - Motif Bio said it will need to raise new funds after the application for its skin infections treatment, iclaprim, was refused by the US drug regulator in its present form.
Read moreMotif Bio may need to raise cash as antibiotic trial accelerates
31st Oct 2016 10:58
(ShareCast News) - As it prepares to list on the Nasdaq, AIM-listed antibiotics developer Motif Bio said it was likely to need extra funding as enrolments for its latest clinical trial were going faster than expected. Patient enrolment in Motif's Revive 1 phase-three trial has exceeded projections a
Read moreMotif Bio raises £22m via share placing
23rd Jun 2015 11:20
Biopharmaceutical company Motif Bio has raised £22m via a conditional share placing with institutional investors. The London-listed group said "the placing is conditional on securing shareholder approval and on a successful qualified infection disease product designation being given to its iclaprim
Read moreMotif Bio signs deal with leading clinical research organisation
1st Jun 2015 11:15
A wholly-owned subsidiary of antibiotic developer Motif Bio has signed letters of intent and interim agreements with a leading global clinical research organisation (CRO). Motif has agreed to invest more than $0.95m under the agreements, which must be paid by the end of July. Under the agreements,
Read moreMotif Bio makes AIM debut, seeks approval for Iclaprim treatment
2nd Apr 2015 11:46
Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation
Read more